Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

105.98 +4.83 (+4.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,717,492
Open 101.95
Bid (Size) 101.20 (1)
Ask (Size) 107.32 (1)
Prev. Close 101.15
Today's Range 101.40 - 107.46
52wk Range 36.90 - 117.23
Shares Outstanding 122,802,694
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
Via Benzinga
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace

Performance

YTD
+71.16%
+71.16%
1 Month
-1.14%
-1.14%
3 Month
+24.27%
+24.27%
6 Month
+59.06%
+59.06%
1 Year
+123.21%
+123.21%

More News

Read More
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
Via Benzinga
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
From Natera, Inc.
Via Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,400 Today
Via Benzinga
Breaking Down Natera: 10 Analysts Share Their Views
Via Benzinga
(NTRA) - Analyzing Natera's Short Interest
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
From Natera, Inc.
Via Business Wire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Via MarketBeat
Key Takeaways From Natera Analyst Ratings
Via Benzinga
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
From Natera, Inc.
Via Business Wire
Amazon, Natera And A Financial Stock: CNBC's 'Final Trades'
Via Benzinga
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
Via Benzinga
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
From Natera, Inc.
Via Business Wire
Ford Motor, Microsoft And 2 Other Stocks Insiders Are Selling
Via Benzinga
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
From Natera, Inc.
Via Business Wire
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.